Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

MEDICAL --- Neurology --- Hypothalamic Neoplasms --- Outcome Assessment (Health Care) --- Pituitary Diseases --- Endocrine Gland Neoplasms --- Neuroectodermal Tumors --- Prognosis --- Neoplasms, Nerve Tissue --- Supratentorial Neoplasms --- Outcome and Process Assessment (Health Care) --- Endocrine System Diseases --- Neoplasms by Site --- Hypothalamic Diseases --- Diagnosis --- Neoplasms, Germ Cell and Embryonal --- Diseases --- Quality of Health Care --- Neoplasms by Histologic Type --- Brain Neoplasms --- Brain Diseases --- Neoplasms --- Health Care Evaluation Mechanisms --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Central Nervous System Diseases --- Central Nervous System Neoplasms --- Health Services Administration --- Health Care Quality, Access, and Evaluation --- Nervous System Diseases --- Nervous System Neoplasms --- Health Care --- Pituitary Neoplasms --- Treatment Outcome --- Craniopharyngioma --- Medicine --- Health & Biological Sciences --- Oncology --- Brain --- Tumors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials.

multiple sclerosis --- inflammation --- oxidative --- biomarker --- sample size --- autoimmune encephalitis --- plasma exchange --- autoimmunity --- immunotherapeutics --- clinical outcomes --- major depression --- bupropion --- S-adenosylmethionine --- vitamin D3 --- yoga --- craniopharyngioma --- fractionated stereotactic radiation treatments --- sphenoid sinusitis --- cranial nerve-VI palsy --- autoimmune diseases --- immune thrombocytopenic purpura --- alemtuzumab --- antibodies against GluR3 peptide --- cognitive impairment --- diagnosis --- neuropsychological assessment --- short intracortical inhibition --- intracortical facilitation --- fampridine --- walking disability --- TSPAN32 --- tetraspanins --- cellular immunity --- memory T cells --- tDCS --- neuroimaging --- positron emission tomography --- cerebral blood flow --- probiotics --- Streptococcus thermophilus --- ST285 --- MBP83–99 peptide --- mannan --- immune modulation --- agonist peptide --- gut microbiome --- gut–brain axis --- metagenomics --- disease-modifying treatments --- MS --- vaccine --- immunomodulation --- carriers --- B cell receptor --- delivery methods --- immunotherapy --- monoclonal antibodies --- T cell receptor --- tolerance --- diagnostic markers --- immunoglobulins --- kappa --- free light chains --- antigen-specific immunotherapies --- tolerogenic vaccines --- tolerance induction --- central nervous system --- myelin peptides --- myelin basic protei --- proteolipid protein --- myelin oligodendrocyte glycoprotein --- nanotechnology --- drug delivery nanosystems --- lipids --- polymers --- vaccines --- nanoparticles --- antigen-specific immunotherapy --- experimental autoimmune encephalomyelitis --- neurodegeneration --- chloroquine --- EAE --- dendritic cells --- microglia --- astrocytes --- oligodendrocytes --- conformational analysis --- peptides --- altered peptide ligands --- NMR spectroscopy --- NOE-constraints --- molecular dynamic --- trimolecular complex --- Multiple Sclerosis --- early-onset --- adult-onset --- Human Leucocyte Antigens --- immunogenetics --- clinical phenotype --- clinical outcome --- therapeutics --- antibody detection --- ELISA --- multivalency --- N-glucosylated peptide epitopes --- peptide --- conjugation --- MOG35-55 --- Graphite/SiO2 electrode --- voltammetry --- HPLC --- MS drugs